February 07, 2019
Health care specialty bank H.C. Wainwright has asked a California federal court to toss a second amended complaint accusing it of fraudulently inflating the stock of pharmaceutical company MannKind Corp., arguing that renewed claims it deliberately issued an unrealistic target price of $6 a share remain unsupported.